Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of KDM5A gene and ATRX gene

A gene and gene mutation technology, applied in the field of application of KDM5A gene and ATRX gene, can solve the problems of few second-line options and lack of treatment methods

Pending Publication Date: 2020-10-02
SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
View PDF5 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In general, there is a lack of effective treatment for SCLC. After the failure of conventional EP or IP regimens, there are few second-line options (such as topotecan, paclitaxel, etc.), and after the failure of second-line therapy, NCCN and other guidelines only recommend supportive treatment or clinical research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of KDM5A gene and ATRX gene
  • Application of KDM5A gene and ATRX gene
  • Application of KDM5A gene and ATRX gene

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Example 1: Phase Ib clinical trial of Theoloni monotherapy in relapsed and refractory small cell lung cancer

[0018] Test drug: Cioroni capsules, specifications: 5mg, 25mg. Produced by Shenzhen Microchip Biotechnology Co., Ltd.

[0019] Dosing regimen: Cioroni capsules are administered at 50 mg / day, QD (no adjustment for body weight or body surface area). Take every morning on an empty stomach with water, swallowing the whole capsule whole. Continuous administration for 28 days constitutes a treatment cycle, and there is no interval between each treatment cycle.

[0020] Number of cases: 25 cases were enrolled.

[0021] standard constrain:

[0022] 1. Age ≥ 18 years old, ≤ 75 years old, gender is not limited;

[0023] 2. Small cell lung cancer confirmed by histology or cytology;

[0024] 3. Disease progression or recurrence occurred after receiving at least 2 different systemic chemotherapy regimens (including platinum-based chemotherapy regimens) in the past;

...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, and discloses an application of a KDM5A gene and an ATRX gene. According to the present invention, progression-free survival (PFS) and objective response rate (ORR) are used as curative effect indicators to verify the correlation between variations on the KDM5A gene and the ATRX gene and the curative effect of Chiauranib. The test on mutation information of the KDM5A gene and the ATRX gene can guide clinical medication of the Chiauranib and evaluate curative effect of the Chiauranib on small cell lung cancer.

Description

[0001] This application claims the priority of the Chinese patent application with the application number 201910228411.9 and the title of the invention "Application of KDM5A gene and ATRX gene" filed with the China Patent Office on March 25, 2019, the entire contents of which are incorporated by reference in this application . technical field [0002] The invention relates to the field of medicine technology, in particular to the application of KDM5A gene and ATRX gene. Background technique [0003] The morbidity and mortality of lung cancer rank first in malignant tumors. Small cell lung cancer (SCLC) accounts for 10% to 15% of the total number of lung cancers. Its clinical characteristics and biological behavior are different from other types of lung cancer, showing a doubling The time is short, the early metastasis is easy to occur, and the degree of malignancy is extremely high. Patients who have not received treatment often die within 2 to 4 months. Although newly trea...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/68G01N33/574
CPCC12Q1/6886G01N33/68G01N33/57423C12Q2600/106C12Q2600/156A61P35/00A61K31/47G01N2800/52C12Q1/6883
Inventor 鲁先平山松潘德思宁志强
Owner SHENZHEN CHIPSCREEN BIOSCIENCES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com